OncoMatch/Clinical Trials/NCT07111507
A Study of Tarlatamab for People With Prostate Cancer
Is NCT07111507 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Tarlatamab for metastatic prostate cancer.
Treatment: Tarlatamab — The researchers are doing this study to find out whether tarlatamab is an effective treatment for Delta-like Protein 3 (DLL3)-positive prostate cancer that has spread to other parts of your body (metastasized) and has either come back after treatment (relapsed) or not responded to treatment (refractory).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Cancer type
Prostate Cancer
Biomarker criteria
Required: DLL3 positive expression (50% or more of tumor cells with dll3 expression by ihc)
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: androgen-deprivation therapy — metastatic
Serum testosterone ≤ 50 ng/dL with ongoing androgen-deprivation therapy (ADT) or de novo small cell NEPC (neither testosterone levels nor ADT are required in participants with de novo small cell NEPC)
Must have received: platinum-based chemotherapy — de novo small cell NEPC
Participants with de novo small cell NEPC are required to have received prior platinum-based chemotherapy or be ineligible for this treatment.
Cannot have received: DLL3-targeting treatment
Prior DLL3-targeting treatment
Lab requirements
Blood counts
ANC ≥ 1,500/μL; Hemoglobin ≥9g/dL; Platelet count ≥75,000/μL
Kidney function
CrCl ≥ 30 mL/min using Cockroft Gault or MDRD calculation
Liver function
Bilirubin ≤ 1.5 ULN or < 2 if liver metastases or Gilbert's disease; SGOT (AST) < 3 x ULN or < 5 if liver metastases; SGPT (ALT) < 3 x ULN or < 5 if liver metastases
Normal organ function with acceptable initial laboratory values within 14 days of treatment start. ANC ≥ 1,500/μL; Hemoglobin ≥9g/dL; Platelet count ≥75,000/μL; Bilirubin ≤ 1.5 ULN or < 2 if liver metastases or Gilbert's disease; SGOT (AST) < 3 x ULN or < 5 if liver metastases; SGPT (ALT) < 3 x ULN or < 5 if liver metastases; CrCl ≥ 30 mL/min using Cockroft Gault or MDRD calculation
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UNIVERSITY OF CALIFORNIA SAN DIEGO (Data collection only) · San Diego, California
- University of California San Francisco · San Francisco, California
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) · Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) · Middletown, New Jersey
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) · Montvale, New Jersey
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07111507 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior DLL3-targeting treatment disqualifies patients from enrollment.
Does this trial require DLL3?
Yes, DLL3 positive expression is a required biomarker for enrollment.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages